Lead Product(s) : Idazoxan
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Terran Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Idazoxan
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Terran Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement